Associate Professor Shuzhao Li at The Jackson Laboratory for Genomic Medicine in Connecticut. Photo by Charles Camarda.
“Metabolomics is biochemistry 2.0,” Li says. Many of these molecules are metabolites, the product of gene functions, he explains, and others have dietary and environmental origins. “So, this chemical information fills a critical gap between genes and environment, to support precision medicine.”
Li started his scientific career in modeling gene pathways in the immune system, but in recent years turned his focus to metabolomics. “The first golden age of biochemistry was the early half of 20th century. With the vast new information we gain from metabolomics, we are entering the second golden age of biochemistry.”
To Li, metabolomics is a powerful new tool added to research arsenal.
“How to manipulate and engineer human immunity is at the center of combating many diseases,” Li says. “We’re now in a new era of integrating genomics, metabolomics, single-cell profiling, immunology and other fields, but we’re still missing a comprehensive and robust computational tool to predict human immune response.”
Li and his lab are pioneering metabolomic applications to human immunology. His earlier works showed that vaccine-induced human immune response is largely influenced by the patient’s metabolic profile, and that arginine depletion mediates viral responses in innate immune cells.
Big data from metabolomics and other high-throughput technologies form the foundation of multiscale models of the human immune system. The most promising future, Li says, harnesses “next-generation artificial intelligence [AI] that continuously learns from big data, and trains to simulate the human immune system.” This will involve data mining, artificial expert systems, deep learning and predictive modeling “of tremendous complexity,” he says. “But the result will be an AI system that is more capable than any single doctor, to guide the design of new drugs, vaccines and immunotherapies.”
Li joined JAX in January 2020 from Emory University in Atlanta, where he was an assistant professor in the Department of Medicine. He will develop a research program in metabolomics and immunometabolomics. This synergizes with JAX’s position in genomic medicine, and traditional strength in computational science and animal models. He is part of the NIH metabolomics consortium, and will expand his research portfolio in immune studies.